NCT04945915

Brief Summary

DAMPs (damage associated molecular patterns) are endogenous molecules that are expressed by cell stress or cell damage and play an important role in tissue (or host) defense and repair by activating the innate immune system. This is not the case with infections or injuries. Briefly, it starts when the immune system is activated by a receptor that recognizes a damage pattern, and it is a generic term for continuous responses by endogenous molecules expressed in this process. Recently, immuno-cancer drugs for cancer treatment by applying this immune response are also emerging. In cardiac surgery using cardiopulmonary bypass (CPB), there are more deleterious effects and adverse effects caused by using CPB than the surgery itself. There are several studies that have revealed the association between DAMPs and the degree of complications by approaching them from the point of view of tissue damage caused by the use of CPB. Therefore, we intend to investigate the changes in DMAPs over time during, and after cardiac surgery and the differences in DAMPs according to the presence or absence of postoperative pulmonary complications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 6, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2020

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

June 16, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 30, 2021

Completed
Last Updated

October 17, 2023

Status Verified

October 1, 2023

Enrollment Period

1.6 years

First QC Date

June 16, 2021

Last Update Submit

October 14, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Concentration of heparan sulfate (HS)

    blood sampling before CPB application, 90 minutes after CPB application, after CPB weaning, the day after surgery

    the day after surgery, up to 48hours

  • Concentration of high mobility group box 1 (HMGB1)

    blood sampling before CPB application, 90 minutes after CPB application, after CPB weaning, the day after surgery

    the day after surgery, up to 48hours

Secondary Outcomes (1)

  • Postoperative complication

    during admission, up to 22 days

Interventions

There was no intervention because this reasearch is observational study.

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing cardiac surgery using cardiopulmonary bypass (CPB)

You may qualify if:

  • Adult patients over 20 years of age
  • Patients undergoing cardiac surgery using cardiopulmonary bypass (CPB)

You may not qualify if:

  • pregnant women and minors
  • the patients who required mechanical life support as follows due to unstable vital signs after CPB weaning, ECMO (extracorporeal membrane oxygenation) IABP (intra-aortic balloon pump)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pusan National University Yangsan Hospital

Yangsan, South Korea

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples were collected four times in total, and 7 ml of blood was collected after induction of anesthesia (T1), 90 minutes after CPB (T2), immediately after weaning from CPB (T3), and on the first day after surgery (T4). It was placed in a serum-separating tube and then centrifuged. Enzyme-linked immune sorbent assay is performed to measure the concentration of heparan sulfate (HS) and high mobility group box 1 (HMGB1) using HS ELISA kit (Finetest, EH4010) and HMGB1 ELISA kit (Solarbio, SEKH-0409), respectively. use.

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Hee Young Kim, MD, PhD

    Pusan National University Yangsan Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical associate professor

Study Record Dates

First Submitted

June 16, 2021

First Posted

June 30, 2021

Study Start

August 6, 2018

Primary Completion

March 30, 2020

Study Completion

March 30, 2020

Last Updated

October 17, 2023

Record last verified: 2023-10

Locations